Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could ditching a common drug boost brain power in schizophrenia?

NCT ID NCT06562608

First seen Feb 13, 2026 · Last updated Jun 23, 2026 · Updated 18 times

Summary

This study looks at whether stopping unnecessary anticholinergic drugs (benztropine or trihexyphenidyl) can improve thinking, quality of life, and brain function in people aged 40-70 with schizophrenia or schizoaffective disorder. Participants will either stay on their medication or have it gradually stopped under routine care, with follow-ups over six months. The goal is to see if reducing these drugs leads to better cognitive performance and daily functioning.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • UPMC Western Psychiatric Hospital/University of Pittsburgh

    RECRUITING

    Pittsburgh, Pennsylvania, 15213, United States

    Contact

    Contact

    Contact Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

deprescription of benztropine or trihexyphenidyl

What this could lead to

If successful, this could show that removing unnecessary anticholinergic drugs improves cognitive function and quality of life in older adults with schizophrenia.

What could go wrong

This is a small, early-phase study with only 105 participants. The benefits may not be large or apply to everyone, and stopping these drugs could cause side effects like movement problems.

Conditions

The condition(s) this trial relates to.

Psychotic Disorders schizoaffective disorder schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.